Premature Ovarian Failure Treatment
Premature Ovarian Failure Treatment
The management of premature ovarian failure is built on replacement rather than on a cure, because the condition is a deficiency rather than something that can be reversed. Oestrogen is given, with a progestogen where the womb is still present, and it is continued until around the age at which the menopause would naturally have occurred, because the organs it protects should still have had it. Running alongside that, and not in place of it, is whatever the patient wants next: where a pregnancy is wanted, the fertility pathway is opened at the same time rather than after the deficiency has been settled, and where it is not, replacement is still given for the same reasons. Where a cause is found that can be treated, it is treated, and where a cause is found that matters to relatives, genetic counselling is arranged. The rest of the plan is the management of consequences that are silent: bone density, cardiovascular risk factors and the genitourinary symptoms.
The two questions that shape the plan
The options are arranged by two questions, and neither of them is about how low the hormone levels are:
- What the oestrogen deficiency needs, which is replacement until the natural age of the menopause. This question has the same answer in every patient, because it is a statement about what the body should still have been producing. It is answered whether the periods stopped recently or years ago, and whether or not a pregnancy is ever wanted.
- What the patient wants next, which decides whether the fertility pathway runs now, later, or not at all. Where a pregnancy is wanted, the options are discussed from the beginning rather than held back until the deficiency is settled, because the routes to a pregnancy have their own timelines. Where it is not part of the plan, nothing about that changes the replacement.
- Anything found along the way that has its own treatment. An autoimmune condition that travels with this one, a thyroid disorder, a raised prolactin, or a cause identified from the history, each has a treatment that is separate from the replacement and is delivered on its own line.
Why the plan is not built around the hormone level. The value confirms the diagnosis and then stops being the thing that decides anything. A lower FSH does not mean less replacement is needed, and a value that shifts does not mean the plan changes. What does change the plan is the age at which the diagnosis was made, what the deficiency has already done, and what the patient wants next.
Replacement, and how long it runs
Oestrogen replacement is the foundation of the plan, and it is replacement rather than treatment in the sense of something given for a fixed course:
- Oestrogen, continued until around the natural age of the menopause. That is the point at which the deficiency would have arrived on its own, and the reason the run is defined that way rather than by a number of years is that the plan is restoring what should have been there for the intervening decades.
- A progestogen alongside the oestrogen wherever the womb is present. Oestrogen given on its own thickens the lining of the womb, and the progestogen is what keeps that in balance. It is not an optional addition while the womb is there, and the route by which it is given depends on what suits the patient.
- A combined hormonal contraceptive, where that suits the patient better. It provides the oestrogen as well as contraception, and it is one of the routes rather than a separate plan. It is chosen with the patient rather than applied by default.
Why this is not the same as the treatment given at the natural menopause. At the natural menopause the same hormones are used, and the conversation there is about the balance of benefit and risk at that age. Here the deficiency is decades early, the organs have decades more to be protected, and the replacement is therefore continued to the age at which it would naturally have been given. The distinction is the reason this is not something to be stopped after a few years as a matter of course.
If a pregnancy is wanted
The fertility question is addressed directly and alongside the replacement rather than after it, and what can be said is bounded in both directions:
- A spontaneous pregnancy is possible and cannot be predicted or excluded. Ovarian function can be intermittent in this condition, so ovulation occurs in some women after the diagnosis and nobody can say in advance which ones. The honest position is that it may happen, that it cannot be engineered or forecast, and that planning does not depend on it.
- Egg donation is the route with the most predictable outcome where a pregnancy is wanted. It does not depend on the remaining function of the ovary, and it is discussed early rather than held as a last resort, because the timeline matters to the decision.
- The uterus is not affected by this condition. The problem is the supply of eggs rather than the capacity to carry a pregnancy, which is the reason donation is a route at all and why the assessment includes the uterus rather than only the ovary.
Why nothing here is promised. Being told that a pregnancy is impossible goes beyond what is known, because function can return intermittently. Being told that it will happen with patience is worse, because it delays a decision that is better made with the facts in front of it. What is offered is the assessment of what remains, the routes with their own predictability, and the time to consider them.
Treating a cause, where one is found
Most of the plan does not depend on finding a cause, and where one is found it is treated on its own line:
- An autoimmune condition, which is one of the treatable lines. Where the assessment identifies thyroid disease or adrenal insufficiency the treatment is for that condition, and it is given whether or not it changes the ovarian picture, because each of them affects health in its own right.
- A genetic finding, which leads to counselling rather than to treatment. A chromosomal abnormality or an FMR1 premutation cannot be reversed, and what changes is what is offered to relatives and to any children. Genetic counselling is arranged because the implications reach beyond the patient.
- Nothing to treat where no cause is found, which is the commonest outcome. The absence of a cause does not leave the plan incomplete, and it does not call for further searching. The deficiency is managed, the consequences are managed, and that is the plan.
Why treating the cause is not the point of the plan. It is natural to expect that once the cause is found the condition can be addressed, and in this condition that is usually not how it works. The two things that a cause changes are whether there is another condition to treat and whether relatives need to be told, and both of those are worth the search. Neither of them changes the need for replacement.
Bone, the heart, and the genitourinary symptoms
The consequences of the deficiency are managed alongside the replacement, and each has measures of its own:
- Bone, which is monitored rather than assumed to be protected. A bone density scan establishes a baseline and is repeated at intervals, and calcium, vitamin D and weight-bearing exercise work with the replacement rather than instead of it. The reason it is measured is that there are no symptoms while bone is being lost.
- The cardiovascular picture, which is reviewed and addressed. Blood pressure, lipids and glucose are part of the plan, and the protection that has been removed early is one of the reasons replacement continues to the natural age rather than stopping before it.
- Vaginal dryness and discomfort during sex, which are treated locally as well as systemically. Local oestrogen acts where it is applied and is used alongside replacement rather than as a substitute for it, and it is offered rather than mentioned only if the patient asks.
Why these are not the second half of the plan. Bone and the cardiovascular system are changing from the moment the deficiency begins, and they do so without producing symptoms. Treating them at the same time as the fertility question rather than after it is what keeps a diagnosis about an ovary from becoming a diagnosis about bone that was found too late.
The plan, and how it is reviewed
The plan is written down at the outset and revisited rather than left to run unattended:
- What is being given, at what dose, by which route, and for how long it is expected to run. Stated in terms of the age at which it will be reviewed against the natural menopause rather than as an open-ended prescription, so that the patient knows what she is taking and why.
- What is being monitored, and at what intervals. Bone density, the cardiovascular risk factors and the symptoms are each reviewed on their own schedule, and the intervals are set out so that the follow-up is arranged rather than left to be requested.
- What would change the plan. A pregnancy being attempted, a change in the symptoms, a new finding on the genetic or autoimmune lines, or a change in the bone result each alters something, and knowing what those triggers are makes the plan usable between appointments.
Why the review is part of the treatment rather than an administrative arrangement. Replacement runs for decades, and the questions attached to it change with age: what is managed at 30 is not what is managed at 45. A plan that is set once and repeated is how the bone result and the cardiovascular picture fall out of view, which is the specific failure this condition is most likely to meet.